

Index

18F-fluorodopa, 55
18F-fluorodopamine, 55
18F-meta-fluorobenzylguanidine, 56

A

Adrenalectomy, 73, 74
Algorithms, 69
Alpha adrenergic blockade, 65
Alpha blocking agents, 66
Analytical methods, 29
Anatomic imaging, 44
Anatomical localization, 65
Anesthetic management, 76
Angiography, 103

B

Beta adrenergic blockade, 65
Beta blockers, 67
Bilateral HNPs, 111
Bilateral pheochromocytoma, 12
Biochemical diagnosis, 23
Biochemical phenotype, 13, 25
Biochemical tests, 27

C

C4Di2Vi tumor
Calcium channel blockers, 68
Carotid body, 81
Catecholamine secretion, 13
Catecholamines, 24, 49
Cavernous sinus, 108
Choice of tests, 26
Clinical classification, 90

Clinical features, 89
Clinical presentations, 100
Clinicopathological features, 81, 99
Clivus, 108
Cluster 1 gene mutation, 13
Computed tomography, 44
Correlation, 88
CT SSTR analogues

D

Developmental origin, 113
Diagnostic evaluation, 33
Diagnostic investigations, 90
Diagnostic workup, 102
Diets, 31
Differential diagnosis, 87
Digital subtraction angiography, 93
Dominant sigmoid sinus, 111
Dopamine, 24
Drugs, 70

E

Embolization, 91
Epidemiology, 81, 82
Epinephrine, 24

F

F-18 Fluorodeoxyglucose, 51
False-positive results, 31, 32
FH, 10
Fisch classification, 101
Foramen magnum, 108
Functional imaging, 14

G

Gallium-68
 Genes, 3, 4,5
 Genetic screening, 2
 Genetics, 1, 81, 82, 113
 Germline mutations, 8,9

H

HIF2A, 8,9, 10
 High-resolution computed tomography, 102
 Histopathology, 84, 115
 Hospital admission, 70

I

I-131 MIBG therapy, 56
 Imaging, 41, 42, 81
 Immunohistochemical phenotype, 13
 Indications, 41
 Indium-111, 50
 Internal carotid artery, 111
 Interpretation, 30
 Intra-atrial stenting, 92
 Intradural extension, 108
 Intratemporal fossa, 104, 106
 Iodine-123, 48
 Iodine-131, 48
 Irreversible alpha blocker, 66

J

Jugular fossa, 103
 Jugulotympanic, 117

L

Large tumours, 108
 Magnetic resonance imaging, 45, 102

Malignant paraganglioma, 77
 Management, 63
 MAX, 10
MDH2, 10
 Medical preparation, 64
 Medications, 31
 MEN2, 7
 Metabolic pathway, 25
 Meta-iodobenzylguanidine scintigraphy, 48
 Metanephrine, 53
 Metastatic behavior, 87
 Metastatic disease, 11
 Metyrosine, 68
 Molecular pathways, 2
 Multifocal tumors, 9
 Multiple HNPs, 111

N

Neuroendocrine tumors, 43
 Neurofibromatosis type 1, 46
 Next-generation sequencing, 14
 NF1, 7
 Non-competitive alpha receptor blocker, 66
 Norepinephrine, 24
 Nuclear scintigraphy, 48

O

Operative technique, 73

P

Paraganglioma, 1, 23, 41, 63, 81, 99
 Pathology, 84,88
 Pediatric, 13
 Peptide receptor, 56
 PGL3, 9
 PGL4, 11

PGL5, 11
Pharmacological, 63
PHD, 6,8,9, 10
Pheochromocytoma, 1,2, 23, 41, 63,
Physiologic imaging, 48
Positron emission tomography, 51
Postoperative management, 78
Preoperative, 72

R

Radionuclide therapy, 56
Radiotherapy, 113
Recurrence, 113
Resection, 73
RET, 6

S

Sampling, 30
SDHx, 9
Shamblin classification, 92
Somatostatin, 50
SPECT/CT, 48, 49
Stent insertion, 110
Stereotactic radiosurgery, 113
Storage conditions, 30
Succinate dehydrogenase, 43
Surgery, 64, 72
Surgical complications, 78
Surgical management, 81, 99

Surgical planning, 92
Surgical principles, 77
Surgical steps, 103
Surgical treatment, 91
Syndromic presentations, 7

T

Temporal bone paraganglioma, 101
Test results, 30
Transcondylar extension, 106, 107
Transtubercular extension, 106, 107
Treatment options, 72
Treatment response evaluation, 56
Tympanojugular, 99

U

Ultrasound, 44
Unilateral sigmoid sinus, 111

V

Vagal paraganglioma, 81
Vertebral artery, 110
VHL, 6, 7

W

Whole body planar images, 49
Workflow, 33